A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment [Un trial randomizzato, di fase 2b, in aperto, sulla somministrazione di JX-594 (Virus vaccinico per GM-CSF e TK disattivato) piu' terapia di supporto ottimale vs. Terapia di supporto ottimale in pazienti affetti da carcinoma epatocellulare avanzato in cui il trattamento con sorafenib e' fallito]

Trial Profile

A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment [Un trial randomizzato, di fase 2b, in aperto, sulla somministrazione di JX-594 (Virus vaccinico per GM-CSF e TK disattivato) piu' terapia di supporto ottimale vs. Terapia di supporto ottimale in pazienti affetti da carcinoma epatocellulare avanzato in cui il trattamento con sorafenib e' fallito]

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2015

At a glance

  • Drugs Pexastimogene devacirepvec (Primary) ; Pexastimogene devacirepvec (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms TRAVERSE
  • Sponsors Jennerex
  • Most Recent Events

    • 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 12 Sep 2013 A decision on the further development of Pexa-Vec in liver cancer will be announced in the fourth quarter of 2013, according to a Transgene media release.
    • 03 Sep 2013 A detailed analysis of the final results of TRAVERSE along with other ongoing studies will be conducted by the end of the year according to a Transgene SA media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top